跳轉至內容
Merck
全部照片(1)

重要文件

P1800000

Pindolol

European Pharmacopoeia (EP) Reference Standard

同義詞:

1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol, 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C14H20N2O2
CAS號碼:
分子量::
248.32
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

pindolol

製造商/商標名

EDQM

mp

167-171 °C (lit.)

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

CC(C)NCC(O)COc1cccc2[nH]ccc12

InChI

1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3

InChI 密鑰

JZQKKSLKJUAGIC-UHFFFAOYSA-N

基因資訊

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Pindolol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

β1-adrenoceptor antagonist; putative 5-HT1A serotonin receptor agonist; vasodilator.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Exclamation mark

訊號詞

Warning

危險分類

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Francesc Artigas et al.
Current drug targets, 7(2), 139-147 (2006-02-16)
Pindolol, a partial beta-adrenoceptor/5-HT1A receptor antagonist was first used to accelerate the onset of action of antidepressant drugs in 1994. Since then, it has been used in more than a dozen controlled trials to examine whether it can reduce the
R Whale et al.
Journal of psychopharmacology (Oxford, England), 24(4), 513-520 (2008-10-04)
Adding pindolol to serotonergic antidepressant treatment offers a potential strategy for producing a more rapid onset of action and an enhanced antidepressant effect. This review investigated whether pindolol enhances the efficacy of serotonergic antidepressant treatment in adult patients with depressive
D Martinez et al.
Biological psychiatry, 48(8), 844-853 (2000-11-07)
Preclinical studies suggest that augmentation of selective serotonin (5-HT) reuptake inhibitors by the 5-HT(1A) receptor agent pindolol might reduce the delay between initiation of treatment and antidepressant response, an effect largely mediated by blockade of 5-HT(1A) autoreceptors in the dorsal
Rebecca Segrave et al.
Human psychopharmacology, 20(3), 163-174 (2005-01-14)
Co-administration of pindolol with SSRIs in patients with depression has been suggested as a way to both hasten and augment antidepressant response. Clinical trials have examined the efficacy of this treatment regime and conflicting results have been reported. The present
A Fanchamps
American heart journal, 104(2 Pt 2), 388-406 (1982-08-01)
The antihypertensive effect of pindolol has been demonstrated in several hundred clinical trials performed in many countries. The results of several representative trials will be reviewed in this article. In a cooperative study of pindolol by Swiss internists, blood pressure

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務